Talampanel

• CAT Number: I002075
• CAS Number: 161832-65-1
• Molecular Formula: C19H19N3O3
• Molecular Weight: 337.37
• Purity: ≥95%
• Target: AMPAR
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• InChI: InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1
• InChIKey: JACAAXNEHGBPOQ-LLVKDONJSA-N
• SMILES: C[C@H]1N(C(C)=O)N=C(C2=CC=C(N)C=C2)C3=CC(OCO4)=C4C=C3C1

Talampanel is a potent and selective AMPA-receptor antagonist, is a potential new antiepileptic drug (AED).Target: AMPA [1]in vitro: Talampanel is a glutamate receptor inhibitor with anti-seizure activity.in vivo： Talampanel reduces motoneuronal calcium in a mouse model of ALS, but its effi cacy declines as the disease progresses, suggesting that medication initiation in the earlier stages of the disease might be more effective. [2]

Reference

1:Pre- and post-exposure talampanel (GYKI 53773) against kainic acid seizures in neonatal rats. Dhir A, Chavda V.Pharmacol Rep. 2016 Feb;68(1):190-5. doi: 10.1016/j.pharep.2015.08.011. Epub 2015 Sep 1. PMID: 26721372 2:Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives. Wang C, Niu L.ACS Chem Neurosci. 2013 Apr 17;4(4):635-44. doi: 10.1021/cn3002398. Epub 2013 Feb 12. PMID: 23402301 Free PMC Article3:Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Paizs M, Tortarolo M, Bendotti C, Engelhardt JI, Siklós L.Amyotroph Lateral Scler. 2011 Sep;12(5):340-4. doi: 10.3109/17482968.2011.584627. Epub 2011 May 30. PMID: 21623665 Free PMC Article4:Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas. Iwamoto FM, Kreisl TN, Kim L, Duic JP, Butman JA, Albert PS, Fine HA.Cancer. 2010 Apr 1;116(7):1776-82. doi: 10.1002/cncr.24957. PMID: 20143438 Free PMC Article5:A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, Clawson L, Haas L, Rothstein JD.Amyotroph Lateral Scler. 2010 May 3;11(3):266-71. doi: 10.3109/17482960903307805. PMID: 19961264 6:Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. Grossman SA, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine HA.J Clin Oncol. 2009 Sep 1;27(25):4155-61. doi: 10.1200/JCO.2008.21.6895. Epub 2009 Jul 27. PMID: 19636006 Free PMC Article7:Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Aujla PK, Fetell MR, Jensen FE.Epilepsia. 2009 Apr;50(4):694-701. doi: 10.1111/j.1528-1167.2008.01947.x. Epub 2009 Feb 12. PMID: 19220413 Free PMC Article8:Talampanel. Howes JF, Bell C.Neurotherapeutics. 2007 Jan;4(1):126-9. Review. PMID: 17199027 9:Talampanel a non-competitive AMPA-antagonist attenuates caspase-3 dependent apoptosis in mouse brain after transient focal cerebral ischemia. Denes L, Szilágyi G, Gál A, Nagy Z.Brain Res Bull. 2006 Jul 31;70(3):260-2. Epub 2006 Mar 31. PMID: 16861112 10:New features in synthesis of talampanel related 2,3-benzodiazepines. Sólyom S, Pallagi I, Abrahám G, Kertész M, Horváth G, Berzsenyi P.Med Chem. 2005 Sep;1(5):481-5. PMID: 16787333